APO Research
Talk to an analyst

APO RESEARCH · REPORT

Specific COX-2 Inhibitors

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Specific COX-2 Inhibitors Industry Growth and Trends Forecast to 2032

27 December 2025110 pages

Choose your research edition.

Industry ResearchSpecific COX-2 Inhibitors Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Specific COX-2 Inhibitors Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Specific COX-2 Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Specific COX-2 Inhibitors Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Specific COX-2 Inhibitors Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Specific COX-2 Inhibitors market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Specific COX-2 Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Specific COX-2 Inhibitors include Actavis, Eskayef Pharmaceuticals, Mylan Pharmaceutical, Neopharmed Gentili, Organon Pharma, Pfizer, Teva, Zentiva and Zydus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Specific COX-2 Inhibitors market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Specific COX-2 Inhibitors market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Specific COX-2 Inhibitors market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Specific COX-2 Inhibitors.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Specific COX-2 Inhibitors market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Specific COX-2 Inhibitors Market by Company

Actavis

Eskayef Pharmaceuticals

Mylan Pharmaceutical

Neopharmed Gentili

Organon Pharma

Pfizer

Teva

Zentiva

Zydus

Beijing Yabao Biological Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Jiangsu Chiatai Qingjiang Pharmaceutical

Qilu Pharmaceutical

Qingdao Baheal Medical

Shanxi Tongda Pharmaceutical

Sichuan Kelun Pharmaceutical

Specific COX-2 Inhibitors Segment by Type

Etoricoxib

Celecoxib

Imrecoxib

Other

Specific COX-2 Inhibitors Segment by Application

Osteoarthritis and Rheumatoid Arthritis

Relieve Acute Pain

Dysmenorrhea

Other

Specific COX-2 Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Specific COX-2 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Specific COX-2 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Specific COX-2 Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Specific COX-2 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Specific COX-2 Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Etoricoxib Table 2. Major Company of Celecoxib Table 3. Major Company of Imrecoxib Table 4. Major Company of Other Table 5. Global Specific COX-2 Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 7. Global Specific COX-2 Inhibitors Sales Market Share in Volume by Type (2021-2026) Table 8. Global Specific COX-2 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 9. Global Specific COX-2 Inhibitors Sales Market Share in Value by Type (2021-2026) Table 10. Global Specific COX-2 Inhibitors Price by Type (2021-2026) & (US$/Unit) Table 11. Global Specific COX-2 Inhibitors Sales by Type (2027-2032) & (K Units) Table 12. Global Specific COX-2 Inhibitors Sales Market Share in Volume by Type (2027-2032) Table 13. Global Specific COX-2 Inhibitors Sales by Type (2027-2032) & (US$ Million) Table 14. Global Specific COX-2 Inhibitors Sales Market Share in Value by Type (2027-2032) Table 15. Global Specific COX-2 Inhibitors Price by Type (2027-2032) & (US$/Unit) Table 16. North America Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 17. North America Specific COX-2 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 19. Europe Specific COX-2 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Specific COX-2 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Latin America Specific COX-2 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Specific COX-2 Inhibitors Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Specific COX-2 Inhibitors Sales by Type (2021-2026) & (US$ Million) Table 26. Specific COX-2 Inhibitors Industry Trends Table 27. Specific COX-2 Inhibitors Industry Drivers Table 28. Specific COX-2 Inhibitors Industry Opportunities and Challenges Table 29. Specific COX-2 Inhibitors Industry Restraints Table 30. Global Specific COX-2 Inhibitors Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Specific COX-2 Inhibitors Revenue Market Share by Company (2021-2026) Table 32. Global Specific COX-2 Inhibitors Sales by Company (2021-2026) & (K Units) Table 33. Global Specific COX-2 Inhibitors Sales Share by Company (2021-2026) Table 34. Global Specific COX-2 Inhibitors Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Specific COX-2 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Specific COX-2 Inhibitors Major Company Production Sites and Headquarters Table 37. Global Specific COX-2 Inhibitors Company, Product Type & Application Table 38. Global Specific COX-2 Inhibitors Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Specific COX-2 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Specific COX-2 Inhibitors Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Specific COX-2 Inhibitors Sales by Region (2021-2026) & (K Units) Table 43. Global Specific COX-2 Inhibitors Sales Market Share in Volume by Region (2021-2026) Table 44. Global Specific COX-2 Inhibitors Sales by Region (2021-2026) & (US$ Million) Table 45. Global Specific COX-2 Inhibitors Sales Market Share in Value by Region (2021-2026) Table 46. Global Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Specific COX-2 Inhibitors Sales by Region (2027-2032) & (K Units) Table 48. Global Specific COX-2 Inhibitors Sales Market Share in Volume by Region (2027-2032) Table 49. Global Specific COX-2 Inhibitors Sales by Region (2027-2032) & (US$ Million) Table 50. Global Specific COX-2 Inhibitors Sales Market Share in Value by Region (2027-2032) Table 51. Global Specific COX-2 Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Specific COX-2 Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 54. Global Specific COX-2 Inhibitors Sales Market Share in Volume by Application (2021-2026) Table 55. Global Specific COX-2 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 56. Global Specific COX-2 Inhibitors Sales Market Share in Value by Application (2021-2026) Table 57. Global Specific COX-2 Inhibitors Price by Application (2021-2026) & (US$/Unit) Table 58. Global Specific COX-2 Inhibitors Sales by Application (2027-2032) & (K Units) Table 59. Global Specific COX-2 Inhibitors Sales Market Share in Volume by Application (2027-2032) Table 60. Global Specific COX-2 Inhibitors Sales by Application (2027-2032) & (US$ Million) Table 61. Global Specific COX-2 Inhibitors Sales Market Share in Value by Application (2027-2032) Table 62. Global Specific COX-2 Inhibitors Price by Application (2027-2032) & (US$/Unit) Table 63. North America Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 64. North America Specific COX-2 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 66. Europe Specific COX-2 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Specific COX-2 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 70. Latin America Specific COX-2 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Specific COX-2 Inhibitors Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Specific COX-2 Inhibitors Sales by Application (2021-2026) & (US$ Million) Table 73. Actavis Company Information Table 74. Actavis Business Overview Table 75. Actavis Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Actavis Specific COX-2 Inhibitors Product Portfolio Table 77. Actavis Recent Development Table 78. Eskayef Pharmaceuticals Company Information Table 79. Eskayef Pharmaceuticals Business Overview Table 80. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 82. Eskayef Pharmaceuticals Recent Development Table 83. Mylan Pharmaceutical Company Information Table 84. Mylan Pharmaceutical Business Overview Table 85. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 87. Mylan Pharmaceutical Recent Development Table 88. Neopharmed Gentili Company Information Table 89. Neopharmed Gentili Business Overview Table 90. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio Table 92. Neopharmed Gentili Recent Development Table 93. Organon Pharma Company Information Table 94. Organon Pharma Business Overview Table 95. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Organon Pharma Specific COX-2 Inhibitors Product Portfolio Table 97. Organon Pharma Recent Development Table 98. Pfizer Company Information Table 99. Pfizer Business Overview Table 100. Pfizer Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pfizer Specific COX-2 Inhibitors Product Portfolio Table 102. Pfizer Recent Development Table 103. Teva Company Information Table 104. Teva Business Overview Table 105. Teva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Teva Specific COX-2 Inhibitors Product Portfolio Table 107. Teva Recent Development Table 108. Zentiva Company Information Table 109. Zentiva Business Overview Table 110. Zentiva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Zentiva Specific COX-2 Inhibitors Product Portfolio Table 112. Zentiva Recent Development Table 113. Zydus Company Information Table 114. Zydus Business Overview Table 115. Zydus Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Zydus Specific COX-2 Inhibitors Product Portfolio Table 117. Zydus Recent Development Table 118. Beijing Yabao Biological Pharmaceutical Company Information Table 119. Beijing Yabao Biological Pharmaceutical Business Overview Table 120. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 122. Beijing Yabao Biological Pharmaceutical Recent Development Table 123. Jiangsu Hengrui Pharmaceuticals Company Information Table 124. Jiangsu Hengrui Pharmaceuticals Business Overview Table 125. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio Table 127. Jiangsu Hengrui Pharmaceuticals Recent Development Table 128. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information Table 129. Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview Table 130. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 132. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Development Table 133. Qilu Pharmaceutical Company Information Table 134. Qilu Pharmaceutical Business Overview Table 135. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 137. Qilu Pharmaceutical Recent Development Table 138. Qingdao Baheal Medical Company Information Table 139. Qingdao Baheal Medical Business Overview Table 140. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio Table 142. Qingdao Baheal Medical Recent Development Table 143. Shanxi Tongda Pharmaceutical Company Information Table 144. Shanxi Tongda Pharmaceutical Business Overview Table 145. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 147. Shanxi Tongda Pharmaceutical Recent Development Table 148. Sichuan Kelun Pharmaceutical Company Information Table 149. Sichuan Kelun Pharmaceutical Business Overview Table 150. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio Table 152. Sichuan Kelun Pharmaceutical Recent Development Table 153. North America Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 154. North America Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 155. North America Specific COX-2 Inhibitors Sales Market Share by Country (2021-2026) Table 156. North America Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 157. North America Specific COX-2 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 158. North America Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. North America Specific COX-2 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 160. North America Specific COX-2 Inhibitors Market Share by Country (2021-2026) Table 161. North America Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. North America Specific COX-2 Inhibitors Market Share Forecast by Country (2027-2032) Table 163. Europe Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 164. Europe Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 165. Europe Specific COX-2 Inhibitors Sales Market Share by Country (2021-2026) Table 166. Europe Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 167. Europe Specific COX-2 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 168. Europe Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Europe Specific COX-2 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 170. Europe Specific COX-2 Inhibitors Market Share by Country (2021-2026) Table 171. Europe Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Europe Specific COX-2 Inhibitors Market Share Forecast by Country (2027-2032) Table 173. Asia-Pacific Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 174. Asia-Pacific Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 175. Asia-Pacific Specific COX-2 Inhibitors Sales Market Share by Country (2021-2026) Table 176. Asia-Pacific Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 177. Asia-Pacific Specific COX-2 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 178. Asia-Pacific Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 179. Asia-Pacific Specific COX-2 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 180. Asia-Pacific Specific COX-2 Inhibitors Market Share by Country (2021-2026) Table 181. Asia-Pacific Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 182. Asia-Pacific Specific COX-2 Inhibitors Market Share Forecast by Country (2027-2032) Table 183. Latin America Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 184. Latin America Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 185. Latin America Specific COX-2 Inhibitors Sales Market Share by Country (2021-2026) Table 186. Latin America Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 187. Latin America Specific COX-2 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 188. Latin America Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 189. Latin America Specific COX-2 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 190. Latin America Specific COX-2 Inhibitors Market Share by Country (2021-2026) Table 191. Latin America Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 192. Latin America Specific COX-2 Inhibitors Market Share Forecast by Country (2027-2032) Table 193. Middle East and Africa Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 194. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021-2026) & (K Units) Table 195. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share by Country (2021-2026) Table 196. Middle East and Africa Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032) & (K Units) Table 197. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share Forecast by Country (2027-2032) Table 198. Middle East and Africa Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. Middle East and Africa Specific COX-2 Inhibitors Market Size by Country (2021-2026) & (US$ Million) Table 200. Middle East and Africa Specific COX-2 Inhibitors Market Share by Country (2021-2026) Table 201. Middle East and Africa Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. Middle East and Africa Specific COX-2 Inhibitors Market Share Forecast by Country (2027-2032) Table 203. Key Raw Materials Table 204. Raw Materials Key Suppliers Table 205. Specific COX-2 Inhibitors Distributors List Table 206. Specific COX-2 Inhibitors Customers List Table 207. Research Programs/Design for This Report Table 208. Authors List of This Report Table 209. Secondary Sources Table 210. Primary Sources List of Figures Figure 1. Specific COX-2 Inhibitors Image Figure 2. Global Specific COX-2 Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Specific COX-2 Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Specific COX-2 Inhibitors Sales (2021-2032) & (K Units) Figure 5. Etoricoxib Image Figure 6. Global Etoricoxib Sales YoY Growth (2021-2032) & (K Units) Figure 7. Celecoxib Image Figure 8. Global Celecoxib Sales YoY Growth (2021-2032) & (K Units) Figure 9. Imrecoxib Image Figure 10. Global Imrecoxib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Other Image Figure 12. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Specific COX-2 Inhibitors Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Specific COX-2 Inhibitors Market Share by Type 2025 VS 2032 Figure 15. North America Specific COX-2 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 16. North America Specific COX-2 Inhibitors Sales Market Share in Value by Type in 2025 Figure 17. Europe Specific COX-2 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 18. Europe Specific COX-2 Inhibitors Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Specific COX-2 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Specific COX-2 Inhibitors Sales Market Share in Value by Type in 2025 Figure 21. Latin America Specific COX-2 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Specific COX-2 Inhibitors Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Specific COX-2 Inhibitors Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Osteoarthritis and Rheumatoid Arthritis Image Figure 28. Global Osteoarthritis and Rheumatoid Arthritis Sales YoY Growth (2021-2032) & (K Units) Figure 29. Relieve Acute Pain Image Figure 30. Global Relieve Acute Pain Sales YoY Growth (2021-2032) & (K Units) Figure 31. Dysmenorrhea Image Figure 32. Global Dysmenorrhea Sales YoY Growth (2021-2032) & (K Units) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Specific COX-2 Inhibitors Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Specific COX-2 Inhibitors Market Share by Application 2025 VS 2032 Figure 37. North America Specific COX-2 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 38. North America Specific COX-2 Inhibitors Sales Market Share in Value by Application in 2025 Figure 39. Europe Specific COX-2 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 40. Europe Specific COX-2 Inhibitors Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Specific COX-2 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Specific COX-2 Inhibitors Sales Market Share in Value by Application in 2025 Figure 43. Latin America Specific COX-2 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Specific COX-2 Inhibitors Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share in Value by Application in 2025 Figure 47. North America Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Specific COX-2 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Specific COX-2 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Specific COX-2 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Specific COX-2 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Specific COX-2 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Specific COX-2 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Specific COX-2 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Specific COX-2 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Specific COX-2 Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Specific COX-2 Inhibitors Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Specific COX-2 Inhibitors Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Specific COX-2 Inhibitors Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Specific COX-2 Inhibitors Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Specific COX-2 Inhibitors Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Etoricoxib
  • Celecoxib
  • Imrecoxib
  • Other
Applications
  • Osteoarthritis and Rheumatoid Arthritis
  • Relieve Acute Pain
  • Dysmenorrhea
  • Other
Companies covered
  • Actavis
  • Eskayef Pharmaceuticals
  • Mylan Pharmaceutical
  • Neopharmed Gentili
  • Organon Pharma
  • Pfizer
  • Teva
  • Zentiva
  • Zydus
  • Beijing Yabao Biological Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Jiangsu Chiatai Qingjiang Pharmaceutical
  • Qilu Pharmaceutical
  • Qingdao Baheal Medical
  • Shanxi Tongda Pharmaceutical
  • Sichuan Kelun Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Specific COX-2 Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Specific COX-2 Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Specific COX-2 Inhibitors Market by Type
  6. 1.3.1 Etoricoxib
  7. 1.3.2 Celecoxib
  8. 1.3.3 Imrecoxib
  9. 1.3.4 Other
  10. 1.4 Global Specific COX-2 Inhibitors Market Size by Type
  11. 1.4.1 Global Specific COX-2 Inhibitors Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Specific COX-2 Inhibitors Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Specific COX-2 Inhibitors Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Specific COX-2 Inhibitors Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Specific COX-2 Inhibitors Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Specific COX-2 Inhibitors Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Specific COX-2 Inhibitors Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Specific COX-2 Inhibitors Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Specific COX-2 Inhibitors Industry Trends
  2. 2.2 Specific COX-2 Inhibitors Industry Drivers
  3. 2.3 Specific COX-2 Inhibitors Industry Opportunities and Challenges
  4. 2.4 Specific COX-2 Inhibitors Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Specific COX-2 Inhibitors Revenue (2021-2026)
  2. 3.2 Global Top Players by Specific COX-2 Inhibitors Sales (2021-2026)
  3. 3.3 Global Top Players by Specific COX-2 Inhibitors Price (2021-2026)
  4. 3.4 Global Specific COX-2 Inhibitors Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Specific COX-2 Inhibitors Major Company Production Sites & Headquarters
  6. 3.6 Global Specific COX-2 Inhibitors Company, Product Type & Application
  7. 3.7 Global Specific COX-2 Inhibitors Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Specific COX-2 Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Specific COX-2 Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Specific COX-2 Inhibitors Tier 1, Tier 2, and Tier 3
4 Specific COX-2 Inhibitors Regional Status and Outlook
  1. 4.1 Global Specific COX-2 Inhibitors Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Specific COX-2 Inhibitors Historic Market Size by Region
  3. 4.2.1 Global Specific COX-2 Inhibitors Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Specific COX-2 Inhibitors Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Specific COX-2 Inhibitors Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Specific COX-2 Inhibitors Forecasted Market Size by Region
  7. 4.3.1 Global Specific COX-2 Inhibitors Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Specific COX-2 Inhibitors Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Specific COX-2 Inhibitors Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Specific COX-2 Inhibitors by Application
  1. 5.1 Specific COX-2 Inhibitors Market by Application
  2. 5.1.1 Osteoarthritis and Rheumatoid Arthritis
  3. 5.1.2 Relieve Acute Pain
  4. 5.1.3 Dysmenorrhea
  5. 5.1.4 Other
  6. 5.2 Global Specific COX-2 Inhibitors Market Size by Application
  7. 5.2.1 Global Specific COX-2 Inhibitors Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Specific COX-2 Inhibitors Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Specific COX-2 Inhibitors Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Specific COX-2 Inhibitors Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Specific COX-2 Inhibitors Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Specific COX-2 Inhibitors Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Specific COX-2 Inhibitors Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Specific COX-2 Inhibitors Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Actavis
  2. 6.1.1 Actavis Company Information
  3. 6.1.2 Actavis Business Overview
  4. 6.1.3 Actavis Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Actavis Specific COX-2 Inhibitors Product Portfolio
  6. 6.1.5 Actavis Recent Developments
  7. 6.2 Eskayef Pharmaceuticals
  8. 6.2.1 Eskayef Pharmaceuticals Company Information
  9. 6.2.2 Eskayef Pharmaceuticals Business Overview
  10. 6.2.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  12. 6.2.5 Eskayef Pharmaceuticals Recent Developments
  13. 6.3 Mylan Pharmaceutical
  14. 6.3.1 Mylan Pharmaceutical Company Information
  15. 6.3.2 Mylan Pharmaceutical Business Overview
  16. 6.3.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  18. 6.3.5 Mylan Pharmaceutical Recent Developments
  19. 6.4 Neopharmed Gentili
  20. 6.4.1 Neopharmed Gentili Company Information
  21. 6.4.2 Neopharmed Gentili Business Overview
  22. 6.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
  24. 6.4.5 Neopharmed Gentili Recent Developments
  25. 6.5 Organon Pharma
  26. 6.5.1 Organon Pharma Company Information
  27. 6.5.2 Organon Pharma Business Overview
  28. 6.5.3 Organon Pharma Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
  30. 6.5.5 Organon Pharma Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Teva
  38. 6.7.1 Teva Company Information
  39. 6.7.2 Teva Business Overview
  40. 6.7.3 Teva Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
  42. 6.7.5 Teva Recent Developments
  43. 6.8 Zentiva
  44. 6.8.1 Zentiva Company Information
  45. 6.8.2 Zentiva Business Overview
  46. 6.8.3 Zentiva Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
  48. 6.8.5 Zentiva Recent Developments
  49. 6.9 Zydus
  50. 6.9.1 Zydus Company Information
  51. 6.9.2 Zydus Business Overview
  52. 6.9.3 Zydus Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Zydus Specific COX-2 Inhibitors Product Portfolio
  54. 6.9.5 Zydus Recent Developments
  55. 6.10 Beijing Yabao Biological Pharmaceutical
  56. 6.10.1 Beijing Yabao Biological Pharmaceutical Company Information
  57. 6.10.2 Beijing Yabao Biological Pharmaceutical Business Overview
  58. 6.10.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  60. 6.10.5 Beijing Yabao Biological Pharmaceutical Recent Developments
  61. 6.11 Jiangsu Hengrui Pharmaceuticals
  62. 6.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 6.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 6.11.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
  66. 6.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 6.12 Jiangsu Chiatai Qingjiang Pharmaceutical
  68. 6.12.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
  69. 6.12.2 Jiangsu Chiatai Qingjiang Pharmaceutical Business Overview
  70. 6.12.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  72. 6.12.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments
  73. 6.13 Qilu Pharmaceutical
  74. 6.13.1 Qilu Pharmaceutical Company Information
  75. 6.13.2 Qilu Pharmaceutical Business Overview
  76. 6.13.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  78. 6.13.5 Qilu Pharmaceutical Recent Developments
  79. 6.14 Qingdao Baheal Medical
  80. 6.14.1 Qingdao Baheal Medical Company Information
  81. 6.14.2 Qingdao Baheal Medical Business Overview
  82. 6.14.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
  84. 6.14.5 Qingdao Baheal Medical Recent Developments
  85. 6.15 Shanxi Tongda Pharmaceutical
  86. 6.15.1 Shanxi Tongda Pharmaceutical Company Information
  87. 6.15.2 Shanxi Tongda Pharmaceutical Business Overview
  88. 6.15.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  90. 6.15.5 Shanxi Tongda Pharmaceutical Recent Developments
  91. 6.16 Sichuan Kelun Pharmaceutical
  92. 6.16.1 Sichuan Kelun Pharmaceutical Company Information
  93. 6.16.2 Sichuan Kelun Pharmaceutical Business Overview
  94. 6.16.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
  96. 6.16.5 Sichuan Kelun Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Specific COX-2 Inhibitors Sales by Country
  2. 7.1.1 North America Specific COX-2 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Specific COX-2 Inhibitors Sales by Country (2021-2026)
  4. 7.1.3 North America Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032)
  5. 7.2 North America Specific COX-2 Inhibitors Market Size by Country
  6. 7.2.1 North America Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Specific COX-2 Inhibitors Market Size by Country (2021-2026)
  8. 7.2.3 North America Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Specific COX-2 Inhibitors Sales by Country
  2. 8.1.1 Europe Specific COX-2 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Specific COX-2 Inhibitors Sales by Country (2021-2026)
  4. 8.1.3 Europe Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Specific COX-2 Inhibitors Market Size by Country
  6. 8.2.1 Europe Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Specific COX-2 Inhibitors Market Size by Country (2021-2026)
  8. 8.2.3 Europe Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Specific COX-2 Inhibitors Sales by Country
  2. 9.1.1 Asia-Pacific Specific COX-2 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Specific COX-2 Inhibitors Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Specific COX-2 Inhibitors Market Size by Country
  6. 9.2.1 Asia-Pacific Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Specific COX-2 Inhibitors Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Specific COX-2 Inhibitors Sales by Country
  2. 10.1.1 South America Specific COX-2 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Specific COX-2 Inhibitors Sales by Country (2021-2026)
  4. 10.1.3 South America Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032)
  5. 10.2 South America Specific COX-2 Inhibitors Market Size by Country
  6. 10.2.1 South America Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Specific COX-2 Inhibitors Market Size by Country (2021-2026)
  8. 10.2.3 South America Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Specific COX-2 Inhibitors Sales by Country
  2. 11.1.1 Middle East and Africa Specific COX-2 Inhibitors Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Specific COX-2 Inhibitors Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country
  6. 11.2.1 Middle East and Africa Specific COX-2 Inhibitors Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Specific COX-2 Inhibitors Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Specific COX-2 Inhibitors Value Chain Analysis
  2. 12.1.1 Specific COX-2 Inhibitors Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Specific COX-2 Inhibitors Production Mode & Process
  7. 12.2 Specific COX-2 Inhibitors Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Specific COX-2 Inhibitors Distributors
  10. 12.2.3 Specific COX-2 Inhibitors Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst